HeartFlow Director Lightcap Acquires 40,000 Shares for Over $1 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 28 2025
0mins
Source: Yahoo Finance
- Share Acquisition: HeartFlow Director Jeffrey Lightcap acquired 40,000 shares on December 16, 2025, at $26.34 per share for a total of $1,053,680, indicating his bullish outlook on the company's future.
- Ownership Structure Shift: This transaction increased Lightcap's direct holdings to 40,000 shares, representing 0.047% of HeartFlow's outstanding shares, marking a shift from indirect to direct ownership, while his indirect holdings remain substantial at 6,697,556 shares.
- Market Reaction: The purchase occurred after HeartFlow's stock hit a 52-week low of $25.38, suggesting Lightcap views the current price as attractive, which may positively influence market sentiment.
- Financial Performance: HeartFlow reported a 41% year-over-year revenue increase to $46.3 million in Q3 2023, despite a widening net loss of $50.9 million, yet Lightcap's acquisition could draw more investor interest in the company's growth potential.
Analyst Views on HTFL
Wall Street analysts forecast HTFL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HTFL is 38.60 USD with a low forecast of 35.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 34.980
Low
35.00
Averages
38.60
High
40.00
Current: 34.980
Low
35.00
Averages
38.60
High
40.00
About HTFL
HeartFlow Inc. is a commercial-stage medical technology company that has pioneered the use of software and artificial intelligence (AI) to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). The Company’s novel HeartFlow Platform uses AI and advanced computational fluid dynamics to create a personalized three-dimensional (3D) model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Roadmap Analysis, FFRCT Analysis and Plaque Analysis. The HeartFlow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. The RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
